Vivani Medical (VANI) reported a net loss of $7.3 million, or $0.08 per basic and diluted share, for the third quarter ended September 30, 2026. The company reported cash, cash equivalents and restricted cash of $15.5 million at quarter-end.
Research and development expense rose to $5.0 million from $4.5 million a year earlier, while general and administrative expense increased to $2.5 million from $2.2 million. Vivani said top-line results from its SLIM-1 Phase 1 trial of NPM-139 are anticipated later this week.
- Third-quarter net loss was $7.25 million, compared with a $6.53 million loss in the prior-year quarter.
- Net loss per common share was $0.08 for both basic and diluted shares, compared with $0.11 a year earlier.
- SLIM-1 enrolled 20 GLP-1-naive participants in Australia and is evaluating low-dose NPM-139 against Wegovy.
- The Cortigent-ClearOne merger remains subject to final regulatory approval and is expected to close shortly after approval.
- Vivani plans to prepare and submit an IND application for NPM-139 in 2027 to support a proposed Phase 2 dose-ranging study.
$VANI Insider Trading Activity
$VANI insiders have traded $VANI stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $VANI stock by insiders over the last 6 months:
- GREGG WILLIAMS has made 3 purchases buying 3,968,252 shares for an estimated $4,999,997 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$VANI Hedge Fund Activity
We have seen 15 institutional investors add shares of $VANI stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EVOKE WEALTH, LLC removed 99,870 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $123,838
- MAI CAPITAL MANAGEMENT added 99,870 shares (+inf%) to their portfolio in Q2 2026, for an estimated $123,838
- MARSHALL WACE, LLP removed 81,108 shares (-87.9%) from their portfolio in Q2 2026, for an estimated $100,573
- GEODE CAPITAL MANAGEMENT, LLC removed 69,123 shares (-11.8%) from their portfolio in Q3 2026, for an estimated $85,712
- GSA CAPITAL PARTNERS LLP added 60,866 shares (+inf%) to their portfolio in Q2 2026, for an estimated $75,473
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 57,940 shares (-67.1%) from their portfolio in Q2 2026, for an estimated $71,845
- UBS GROUP AG removed 50,906 shares (-99.6%) from their portfolio in Q3 2026, for an estimated $63,123
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
